Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
How do you decide between escalation to a high efficacy DMT versus switching to a different moderate efficacy DMT in patients with poorly controlled multiple sclerosis?
Related Questions
Do you see a current or future clinical role of neurofilament light chain in the diagnosis or workup of multiple sclerosis?
How do you distinguish between primary progressive MS versus relapsing remitting MS with superimposed relapses in a newly diagnosed patient that is naive to treatment?
How do you use optical coherence tomography in the diagnosis and management of patients with multiple sclerosis and related diseases?
What do you consider when deciding to use a high-efficacy DMT as an initial treatment in multiple sclerosis?
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
What is your approach to dosing rituximab in patients with multiple sclerosis?
How are you using CSF cytokine panels in autoimmune encephalitis, if at all?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
What baseline visual testing, if any, do you recommend at diagnosis for patients with multiple sclerosis who deny visual complaints?
